Form D · Biotechnology

ASLAN Pharmaceuticals Ltd

Singapore, U0 · CIK 0001722926

Offering snapshot reported Mar 28, 2024 · SEC filing

Reported sold
$5M
Offering amount: $5M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 14, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 28, 2024Initial$5,000,000No comparison4SEC filing
Apr 26, 2023Initial$20,000,000No comparison7SEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-508966
Unregistered Warrants to purchase up to 125,000,000 ordinary shares in the form of 5,000,000 American Depositary Shares, or ADSs. Each ADS represents twenty-five ordinary shares. Offering and Sales Amounts exclude cashless exercise.

Source: Form D, filed Mar 28, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kiran Asarpota Executive
Stephen Doyle Executive
Carl Firth, Ph.D. Director, Executive
Ben Goodger Executive
Neil Graham, Mbbs, M.D., Mph Director
Robert E. Hoffman Director
Andrew Howden Director
Alexandre Kaoukhov Executive
Kathleen M. Metters Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3 Temasek Avenue Level 18 Centennial Tower
Singapore, U0, 039190